A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with CAIX-positive cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515607-19-00

Acronym

PH-CAIXGA-02/24

Enrollment

Registered

2024-11-27

Start date

2025-03-19

Completion date

2025-11-28

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with suspected clear cell renal cell carcinoma (ccRCC)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026